Prosecution Insights
Last updated: May 29, 2026

Sage Therapeutics Inc.

7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
6
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (29%)
0
Easy (0%)
5
Unknown (71%)

Rejection Statute Mix

BucketCases
§103 only2 (29%)
No statute on record5 (71%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHIM, DAVID M. 1 58.8% +56.0%
ELENISTE, PIERRE PAUL 1 38.5% +30.2%
CHICKS, ASHLI ARIANA 1 64.1% +44.9%
HOWELL, THEODORE R 1 66.8% +25.4%
MOU, LIYUAN 1 43.2% +58.1%
HUI, SAN MING R 1 59.0% +20.0%
NOTTINGHAM, KYLE GREGORY 1 60.8% +33.8%

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18546616 USE OF NEUROACTIVE STEROID FOR TREATMENT OF SEXUAL DYSFUNCTION CHICKS, ASHLI ARIANA 74d overdue
17993020 NEUROACTIVE STEROIDS AND THEIR METHODS OF USE HUI, SAN MING R 72d overdue
18550724 A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ELENISTE, PIERRE PAUL 42d overdue
17620303 COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS NOTTINGHAM, KYLE GREGORY 17d overdue
18201885 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF MOU, LIYUAN 10d overdue
18557691 19-NOR C3,3-DISUBSTITUTED C21 -N-PYRAZOLYL STEROID FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER AND POSTPARTUM DEPRESSION SHIM, DAVID M. 22d
18216057 OXYSTEROLS AND METHODS OF USE THEREOF HOWELL, THEODORE R 39d

Top Art Units

Art UnitApps
1626 2
1628 2
1622 1
1627 1
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18557691 19-NOR C3,3-DISUBSTITUTED C21 -N-PYRAZOLYL STEROID FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER AND POSTPARTUM DEPRESSION SHIM, DAVID M. 1626 §103 Non-Final OA 22d Pending Oct 27, 2023
18550724 A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ELENISTE, PIERRE PAUL 1622 Other Non-Final OA 42d overdue Pending Sep 15, 2023
18546616 USE OF NEUROACTIVE STEROID FOR TREATMENT OF SEXUAL DYSFUNCTION CHICKS, ASHLI ARIANA 1626 §103 Non-Final OA 74d overdue Pending Aug 16, 2023
18216057 OXYSTEROLS AND METHODS OF USE THEREOF HOWELL, THEODORE R 1628 Other Final Rejection 39d Pending Jun 29, 2023
18201885 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF MOU, LIYUAN 1628 Other Non-Final OA 10d overdue Pending May 25, 2023
17993020 NEUROACTIVE STEROIDS AND THEIR METHODS OF USE HUI, SAN MING R 1627 Other Non-Final OA 72d overdue Pending Nov 23, 2022
17620303 COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS NOTTINGHAM, KYLE GREGORY 1621 Other Non-Final OA 17d overdue Pending Dec 17, 2021

Managing Sage Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month